A Novel Limb Cryocompression System for Prevention of Chemotherapy Induced Peripheral Neuropathy - Expansion Study - Trial NCT05606068
Access comprehensive clinical trial information for NCT05606068 through Pure Global AI's free database. This phase not specified trial is sponsored by National University Hospital, Singapore and is currently Not yet recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Paxman Limb Cryocompression System (PLCS)
Interventional
device
Sponsor & Location
National University Hospital, Singapore
Timeline & Enrollment
N/A
Nov 03, 2022
Nov 01, 2024
Primary Outcome
Incidence of Treatment-Emergent Adverse Events in cancer patients, over the duration of a limb cryocompression cycle, as assessed by Common Terminology Criteria for Adverse Events 5.0,Difference in qualitative symptom scores using the European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale
Summary
The study conducted on cancer patients is designed to test safety and efficacy of limb
 hypothermia in cancer patients using the new Paxman Limb Cryocompression System (PLCS).
 Ultimately this will lead to the development of a therapy regime that will help to prevent
 chemotherapy-induced neuropathy in cancer patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05606068
Device Trial